We previously mapped a locus on chromosome 6 with a large effect (LOD>6) on aortic lesion size in a (C57BL/6JxCAST/Ei) F2 cross and identified arachidonate 5-lipoxygenase (5LO) as a candidate gene in this region. Subsequent studies with the 5LO knock-out model showed effects on atherosclerosis and aortic aneurysms. We now report detailed genetic analysis of the chromosome 6 locus. We created a panel of overlapping and reciprocal subcongenic lines from the B6.CAST Ldlr -/-chromosome 6 congenic strain (CON6.Ldlr -/-) and analyzed aortic lesion size in different subcongenic lines. Our results revealed that there are at least two subregions, designated as Ath37 and Ath38, which affect the size of aortic lesions independent of 5LO. We also showed that homozygote 5LO null mice develop smaller atherosclerotic lesions. We conclude that the relation between the mouse chromosome 6 locus and atherosclerosis is complex and is due to at least two genes with large effects within this region. This complexity should be considered when interpreting results of knock-out studies.
INTRODUCTION
Atherosclerosis is a chronic inflammatory disease which is influenced by a large number of environmental and genetic factors (LUSIS 2000) . Roberts and Thompson originally showed that inbred mouse strains differ in susceptibility to atherosclerosis (ROBERTS and THOMPSON 1976) , and subsequently Paigen and colleagues mapped the first genomic regions linked to atherosclerosis development in mice (Ath1, Ath2, and Ath3) (PAIGEN et al. 1987; PAIGEN et al. 1989 ). At present, over 20 loci contributing to atherosclerosis susceptibility have been identified in crosses between various strains of mice WANG et al. 2005a) . Recently, Tnfsf4 was identified as the gene underlying the Ath1 locus and polymorphisms of this gene were found to be associated with myocardial infarction in humans (WANG et al. 2005b) .
Several years ago, we reported the presence of linkage between the middle/distal segment of chromosome 6 and the size of atheroma (LOD =6.7) in 250 F2 mice generated from the athero-susceptible C57BL/6J (B6) and athero-resistant CAST/Ei (CAST) parental strains (MEHRABIAN et al. 2001) . In this cross, the CAST allele was associated with decreased aortic lesions. The genetic effect of the chromosome 6 locus on lesion size was subsequently confirmed by introgressing this locus from CAST onto the B6 background and analyzing the lesion area in the congenic strain (CON6). Similarly, when CON6 mice on the low density receptor null background (Ldlr -/-) were fed with a high-fat diet they had reduced lesion size compared with the B6.Ldlr -/-mice despite hypercholesterolemia, suggesting that this locus influences lesion development by a mechanism distinct from lipid metabolism (MEHRABIAN et al. 2001 ).
Arachidonate 5-lipoxygenase (5LO) is an enzyme that converts arachidonic acid to various leukotrienes, which are potent pro-inflammatory mediators (MEHRABIAN and ALLAYEE 2003) . The 5LO gene is located within the CON6 locus, and our results showed that the CAST allele of 5LO exhibits decreased levels of both 5LO mRNA and protein (MEHRABIAN et al. 2002) . Furthermore, 5LO +/-Ldlr -/-mice fed with western diet developed significantly smaller lesions compared to the B6 Ldlr -/-. Moreover, resistance to atherosclerosis by the chromosome 6 congenic region or the 5LO knock-out was mediated, in part, by bone marrow derived cells as judged by bone marrow transplantation experiments, consistent with a role for 5LO (MEHRABIAN et al. 2002; MEHRABIAN et al. 2001) . From this work, we concluded that 5LO is a primary candidate gene in the CON6 locus (MEHRABIAN et al. 2002) .
Other studies have confirmed that the 5LO pathway plays a critical role in atherosclerosis. In two separate mouse studies with 5LO inhibitors, it was shown that blocking the 5LO pathway results in reduced atherosclerosis (AIELLO et al. 2002) , especially during early lesion development (SUBBARAO et al. 2004) . In humans, there is an abundance of cells expressing 5LO in the atherosclerotic lesions (SPANBROEK et al. 2003) . We also found significant association between promoter variants of 5LO and intima-media thickness of the carotid artery (DWYER et al. 2004) . Similarly, variants of the 5LO activating protein (FLAP) and LTA4 hydrolase (LTA4H) genes were found to be associated with the risk of stroke and myocardial infarction HELGADOTTIR et al. 2006; HELGADOTTIR et al. 2004) . Recently, Hakonarson et al showed that short term treatment of coronary artery disease patients with a FLAP inhibitor significantly reduced the levels of biomarkers associated with risk of myocardial infarction (HAKONARSON et al. 2005) , and Cipollone and colleagues found that the expression level of 5-LO is elevated in symptomatic compared to asymptomatic plaques and is associated with acute ischemic syndromes (CIPOLLONE et al. 2005) .
Despite the mounting evidence favoring the hypothesis that 5LO pathway plays a role in atherosclerosis, a recent study by Zhao et al observed little or no effect of a 5LO knock-out on atherosclerosis when studied on either Ldlr -/-or apolipoprotein E null (Apoe -/-) backgrounds. However, they observed that 5LO -/-apoE -/-mice developed fewer aneurysms than Apoe -/-mice. In light of the supporting evidence favoring the role of the 5LO pathway in atherosclerosis from both mouse and human studies, we reasoned that the differing conclusions drawn from this study may be due to the complexity of the 5LO locus. If the chromosome 6 region flanking the 5LO gene contains other genes that influence atherosclerosis or aneurysm development, then studies of the 5LO knockout mice could be complicated by variations between the knockout and the control mice in the flanking region of 5LO, unrelated to the 5LO gene itself. That is, since the knockout was created on the129 genetic background and then backcrossed to a B6 background by a series of crosses, the region around 5LO will retain genes derived from strain 129 rather than B6.
Besides 5LO, there are other genes in the chromosome 6 locus, such as PPARgamma (PPARγ), CD163, and alpha 2-macroglobulin (A2m), which have been previously associated with atherosclerosis and other known risk factors for cardiovascular disease in humans or animals (CHAWLA et al. 2001; CHEN et al. 2001; KRIMBOU et al. 2001; LI et al. 2000; SCHAER 2002) . This, coupled with the growing evidence that some of the QTLs for complex traits consist of multiple closely linked causal genes (DIAMENT and WARDEN 2004; FLINT et al. 2005; LEGARE and FRANKEL 2000; LIU et al. 2002; ROGNER et al. 2001; YALCIN et al. 2004 ) lead us to hypothesize that chromosome 6 locus may also represent such a multigenic region. To examine this, we created a panel of overlapping and reciprocal subcongenic lines from CON6.Ldlr -/-mice and characterized each line for development of atheroma in the proximal aorta. Our results showed that the chromosome 6 locus contains at least two genes influencing atherosclerosis. 
MATERIALS AND METHODS

Animals, Diets, and Markers
Aortic Lesion and Aneurysm Analysis
Methods for the quantification of atherosclerotic lesions in the aortic root have previously been reported (MEHRABIAN et al. 2002) . In brief, the heart and proximal aorta were dissected, washed with phosphate-buffered saline, embedded in optimal cutting temperature (OCT) compound (Tissue-Tek), and then frozen on dry ice. Serial 10-µm-thick cryosections from the middle portion of the ventricle to the aortic arch were collected on superfrost/plus microscope slides (Fisher number 12 to 550-15). In the region beginning at the aortic valves, every other section was collected. In all other regions, every fifth section was collected. Sections were then stained with Oil red-O and hematoxylin and counter-stained with Fast Green. Lesion areas were quantified by light microscopy.
To determine the percent incidence and degree of severity of aneurysms in aortic sections, we used a semi-quantitative method which took into account the extent of medial destruction as well as the number of sections in which aneurysms occurred (SHI et al. 2003) . With this method each section examined received a score of between zero and six, with zero being no aneurysm (no disruption of the media) and six being complete destruction of the media with the elastin layer being disrupted for > 2µm and the aortic lesion being protruded into the adventitia. More details on quantitation and representative figure of each score (1 through 6) is provided in the Supplemental Figure 1 . The "Relative Score" for aneurysms were calculated by summing over all the scores of the aortic sections examined for each mouse.
Statistical Analysis
The lesion data are presented as a scattergram with the mean for each group indicated on the graph. The results mentioned in the text are the means and the standard errors. The ANOVA t test was performed using Statview (version 5.0) (Abacus Concepts, Inc) to compare differences between groups in atherosclerotic lesions. The chi-squared test was implemented to compare the difference in the frequency of occurrence of aneurysms between the subcongenics with B6 5LO and subcongenics with CAST 5LO.
In all the tests applied, differences were considered statistically significant at P<0.05.
RESULTS
Construction of CON6 subcongenic lines
To analyze the effect of chromosome 6 locus on lesion size and refine this genetic region, we created a panel of overlapping and reciprocal subcongenic lines. Overall, a total of 16 lines were constructed ( Figure 1A ). This was achieved by intercrossing Recombinant mice were then selected and intercrossed to produce a series of homozygous subcongenic lines. Each subcongenic line is genetically distinct from the others in terms of the length and the boundaries of the CAST introgressed region.
The chromosome 6 locus contains more than one gene affecting atherosclerosis
To investigate if the genetic effect of the CON6 locus on atherosclerosis is due to one or multiple genes, we compared the size of aortic lesions in two subcongenics which divided the CON6 locus into two non-overlapping halves (lines 3 and 10). In subcongenic line 3, the proximal region is derived from CAST strain, with the proximal recombination break point located between D6Mit152 and D6Mit123 and the distal recombination breakpoint located between D6Mit44 and D6Mit193 ( Figure 1A ). In subcongenic line 10, the distal region of the CON6 locus is derived from the CAST strain. In this line, the proximal recombination break point is located between D6Mit193 and D6Mit61 and the distal recombination breakpoint is located between D6Mit14 and the end of the chromosome 6 ( Figure 1A ). Since these two subcongenic lines retained no overlapping CAST region, we were able to study the effect of each region on atherosclerosis independent of the other.
After feeding each line and the parental strains with a high fat "western" diet for 8
weeks, the size of the atherosclerotic lesions was quantified in Oil red-O stained ascending aortic sections (see Methods). In subcongenic line 3, the size of the lesions was significantly smaller than the B6.Ldlr -/-mice (p<0.0001) ( Figure 1B) . Likewise, line 10 developed smaller atheroma compared to the B6.Ldlr -/-mice (p<0.0001) ( Figure 1B ).
There was no significant difference between the size of the lesions in lines 3 and 10.
When compared to the lesion size of the CON6.Ldlr -/-mice, both subcongenic lines had slightly higher average lesion size values (CON6.Ldlr -/-= 57,000 µm 2 /section +/-39,000
vs line 3 = 81,000 µm 2 /section +/-46,000 and line 10 = 78,000 µm 2 /section +/-36,000).
However, these differences were not statistically significant for either line 3 (p = 0.16) or line 10 (p = 0.19). These results show that the effect of the CON6 locus on atherosclerosis could be attributed to at least two sub-regions. The first sub-region (herein referred to the "proximal region") is located between D6Mit152 and D6Mit193 and the second subregion (herein referred to the "distal region") is located distal to D6Mit193 marker.
Fine mapping of the distal region
The distal region spans approximately 25Mb and contains 277 annotated genes. In order to find the smallest interval associated with lesion formation in the distal region, we compared the phenotype of subcongenics 11, 12, 13, 14, and 15, which share overlapping CAST segments in the distal region. that at the telomeric end of chromosome 6, outside the 10Mb interval surrounding the D6Mit111 marker, there are at least two genes linked in repulsion with small but significant effects on lesion formation ( Figure 2B ). alleles for D6Mit220, D6Mit301, and D6Mit258, which again indicates that the protective gene(s) is located proximal to the D6Mit258 marker. In summary, these data allowed us to narrow the distal region to the 7.8 Mb interval between markers D6Mit61 and D6Mit258 for the QTL with the major effect. We designate the gene in the distal region Ath38 ( Figure 2B ).
Complex inheritance of the proximal region
We next focused on the proximal region. To carry the genetic analysis of this region, we created and characterized subcongenic line 16 ( Figures 1A and 1B) . The marker pattern ( Figure 1A) shows that the CAST region retained in this line is the region surrounding marker D6Mit193 but excluding the 5LO gene. To determine the size of the proximal region, we genotyped line 16 with 4 additional markers on each side of D6Mit193. The results showed that the proximal recombination break point is located between D6Mit115 and D6Mit109 and the distal recombination break point is between D6Mit218 and D6Mit61. Since this line had the B6 alleles of both the 5LO and the distal region, we concluded that within the proximal region, the 12Mb interval between D6Mit115 and D6Mit61 contains at least one atheroprotective gene. We designate this gene Ath37 ( Figure 2B ).
5LO null mice develop smaller lesions during the initial stages of atherosclerosis
As discussed above, multiple studies involving inhibitors of the 5LO pathway and disruption of leukotriene receptors have suggested that 5LO deficiency protects against atherosclerosis and that the effect of 5LO is strongest during early stages of atherosclerosis (AIELLO et al. 2002; SUBBARAO et al. 2004) . To test if the effect of 5LO is strongest during the initial stages of lesion development, we examined the effect of the 5LO deficiency on atherosclerosis in a diet-induced model that results primarily from the development of fatty streak lesions (NISHINA et al. 1993) . As shown in Figure 3 , 5LO -/-mice exhibited considerably reduced atherosclerosis compared to C57BL/6J mice in the diet-induced system (~10 fold). These data are consistent with other studies suggesting that reduced 5LO activity has a larger effect on the development of early lesions as compared to more advanced lesions. However, it is important to note that the 5LO -/-mice used here and in other studies ) carry flanking genes derived from strain 129 rather than the B6 strain. Genotyping of the 5LO -/-mice used in our study revealed that the 129-derived region extends from at least markers D6Mit55 to D6Mit333 and thus overlaps with the Ath30 locus we mapped in this study.
The CAST 5LO locus does not influence the development of aneurysms in the proximal aorta Zhao et al (2004) reported that 5LO deficiency decreases the frequency and severity of both abdominal and aortic medial elastic lamina destruction (aneurysm) in hyperlipidemic background. Therefore, we asked if the 5LO CAST allele, with dramatically decreased 5LO activity as compared to the B6 allele, has a similar effect in subcongenic lines. To determine this, we divided the subcongenics into two groups based on homozygosity for the parental 5LO genotype and scored aortic arch sections for the presence or absence of aneurysms. In cases where aneurysms were present, they were scored on a scale zero to six using predetermined criteria based on the morphology of the aortic section (see Materials and Methods and Supplemental Figure 1) . The results of this analysis showed no significant differences in the frequency of aneurysms between homozygous subcongenic lines bearing the CAST 5LO allele and those containing the B6 5LO allele. In addition, among the mice having aneurysms, there were no significant differences in regard to the severity of the aneurysms in these two groups (Figure 4 ).
DISCUSSION
We performed fine mapping of the CON6 locus using a panel of 16 reciprocal and overlapping subcongenic lines. This panel offers several advantages for studying the genetic effects of different subregions within a QTL. First, similar to the recombinant inbred mice, each line is genetically homogeneous, allowing a large number of mice of each genotype to be tested. The ability to examine multiple mice of each line is especially important in studying complex traits such as atherosclerosis in which environmental and other non-genetic factors cause large variations in the phenotype. Moreover, these subcongenic lines can now be studied for other traits that may be associated with the atherosclerotic phenotype. Also, such a panel allows for the simultaneous detection of multiple genes contributing to the phenotype and their fine mapping. For our study, the combined analyses of the CON6.Ldlr -/-subcongenic panel allowed us to identify and fine map two major genes that conferred aortic lesion resistance ( Figure 2B ). Although 7.8
Mb was the best resolution we achieved in our study, one could achieve a higher fine mapping resolution using this strategy by developing more overlapping subcongenics within the locus of interest. Another advantage of using subcongenic lines is that it allows one to test the presence of gene-gene interactions between genes located in separate subregions represented in the panel (LEGARE and FRANKEL 2000; ROGNER et al. 2001 ).
For example, in our data, Ath37 and Ath38 reduced the lesion size by 43% and 41%
respectively. If these two loci acted independently, one might expect to see an approximately additive protective effect on lesion size when the two are combined.
However, the CON6.Ldlr -/-mice, which contain both the proximal and the distal loci, exhibit only a slightly increased protective phenotype, suggesting that there may be an epistatic interaction between these two loci.
Although we observed that there are at least two other genes at the chromosome 6 locus that contribute to lesion development, our results are consistent with previous evidence that 5LO affects atherosclerosis (DWYER et al. 2004; HELGADOTTIR et al. 2004; HUANG et al. 2004; MEHRABIAN et al. 2001) , at least in earlier stages. Recently, however, Zhao et al observed inconsistent effects of 5LO deficiency on the background of the Apoe null mutation in two separately maintained colonies . In this study, one colony showed a 25% decrease in lesions and the other showed no difference. These authors also failed to observe significant differences in lesion development between the 5LO -/-Ldlr -/-double knock-out and the Ldlr -/-mice . They, however, did observe an effect of 5LO deficiency on the frequency and severity of aneurysms in Apoe -/-mice . In contrast, we observed a significant reduction in lesion size in 5LO null homozygous mice compared to wild type B6 mice and no evidence for aneurysms in the subcongenic lines with CAST 5LO hypomorph allele. These differing findings may be due to differences in experimental design such as the methodology for lesion and aneurysm quantitation, the age of the animals, and/or type and length of the diet, all of which differed in some respects. One significant difference in experimental design was that Zhao et al. (2004) assessed aneurysms in the distal aorta whereas we studied aneurysms in the proximal aorta.
However, in light of the study presented here, a plausible explanation would be that there are genetic factors differing between the two studies that confound the results. In particular, it could be that the presence of 129 genomic DNA flanking the targeted allele of 5LO could influence lesion or aneurysm development. Here we provide evidence that two regions distal to 5LO contain genes that affect atherosclerosis. Genotyping of the 5LO -/-mice which were obtained from the Jackson Laboratory and used in our study indicates that in this colony the 14 Mb region surrounding the targeted 5LO gene consists of the 129 genomic sequence. How much of the 129 genomic DNA remained in the 5LO -/-mouse used by Zhao et al (2004) is not known. But clearly, given that multiple genes at the chromosome 6 locus affect atherosclerosis, the extent of the 129 flanking region could influence the results if strain 129 differed from strain B6 with respect to alleles of these genes. We acknowledge that in our report the evidence for the anti-atherogenic effects of loss of 5LO in the 5LO null mice may be confounded by the presence of the Ath30 129 allele surrounding the targeted 5LO gene. In addition, we were unable to genetically isolate the 5LO CAST allele from the Ath30 locus to directly investigate the effect of the CAST 5LO on atherosclerosis. However, the results obtained from the 5LO null mice are consistent with other mouse (AIELLO et al. 2002; SUBBARAO et al. 2004) and human studies (CIPOLLONE et al. 2005; DWYER et al. 2004; HELGADOTTIR et al. 2005; HELGADOTTIR et al. 2004 ) which collectively point toward the importance of the 5LO pathway in pathogenesis of atherosclerosis. It is noteworthy that recent studies have
shown that 5LO deficiency results in complex metabolic effects, including adiposity and insulin resistance (MEHRABIAN et al. 2005) . These effects predict that 5LO deficiency would result in increased atherosclerosis, but yet inhibition of 5LO pathway, both genetically and pharmacologically, results in reduced atherosclerosis. These results combined suggest that 5LO deficiency both promotes atherogenesis (through its metabolic effects) and blocks atherosclerosis (perhaps due to its local effects in the subendothelial space in arteries) with the latter being dominant, at least in the early stages of atherosclerosis.
Our studies have revealed two novel major atherosclerosis genes, neither of which significantly impact lipoprotein levels. The more proximal locus (designated Ath37) spans 12.1 Mb between markers D6Mit115 and D6Mit61. This interval contains 175 genes and includes several candidate genes. One of the candidate genes located in this interval is Adiponectin receptor 2 (Adipor2) (KADOWAKI and YAMAUCHI 2005; SHIMADA et al. 2004) . The natural ligand of Adipor2 is adiponectin which in both animal and human studies have been shown to have anti-atherogenic effects (KADOWAKI and YAMAUCHI 2005) . In summary, in humans, plasma adiponectin levels is inversely correlated with marker for coronary artery disease, the circulating C-reactive protein (OUCHI et al. 2003) . In mice, adenovirus mediated overexpression of adiponectin resulted in reduced progression of atherosclerosis in Apoe-/-mice (OKAMOTO et al. 2002) . In addition, adiponectin stimulates endothelial cells to produce nitric oxide (CHEN et al. 2003a ) and decreases lipid accumulation in human monocyte-derived macrophages by suppressing the expression of class A scavenger receptor (OUCHI et al. 2001) . Since adiponectin has many antiatherogenic effects and because it is known to only bind and act through Adipor1 or Adipor2, it would be plausible to hypothesize that some of the anti-atherogenic effects of adiponectin is mediated through Adipor2. CD163 the macrophage specific scavenger receptor for hemoglobin-haptoglobin complex is another candidate gene located in Ath37 locus (SCHAER 2002) . A recent study by Aristoteli et al showed that the plasma levels of CD163 which previously was found to be present in human atherosclerotic lesions (RATCLIFFE et al. 2001 ) is a significant predictor of coronary artery disease in humans (ARISTOTELI et al. 2006) . Although the exact role of CD163 in the pathogenesis of atherosclerosis is not known, the ability of IL-6 to increase expression of cell surface CD163 protein (BUECHLER et al. 2000) and to induce hemeoxygenase-1 (HO-1) mRNA expression has lead to the speculation that internalization of hemoglobin-haptoglobin complex by CD163 is an initial event in production of anti-inflammatory heme metabolites by HO-1 (MOESTRUP and MOLLER 2004) . The third candidate gene located in the Ath37 region is alpha-2-macroglobulin (A2m). A2m is known to interact with lecithin:cholesterol acyltransferase (LCAT) and enhance its clearance (KRIMBOU et al. 2001) . Since LCAT plays a major role in reverse cholesterol transport and regulation of the plasma high density lipoprotein (HDL) levels, it is plausible to hypothesize that A2m-enhanced clearance of LCAT can lead to lower plasma HDL levels and increase atherosclerosis.
The more distal locus (designated Ath38) spans 7.8 Mb between markers D6Mit61 and D6Mit258. This locus contains 92 annotated genes including a candidate gene, Olr1. Olr1 is known to be expressed in macrophages and vascular endothelial cells and is inducible by variety of pro-inflammatory cytokines (MORAWIETZ et al. 2001; MORAWIETZ et al. 1999; NAGASE et al. 1998) . Moreover this gene has been found to be abundantly present in human (KATAOKA et al. 1999) and rabbit atherosclerotic lesions (CHEN et al. 2000) . Several independent studies have also found evidence for association between OLR1 and acute myocardial infarction (TATSUGUCHI et al. 2003 , MANGO et al. 2003 and coronary artery disease (CHEN et al. 2003b; OHMORI et al. 2004) . Perhaps the most direct evidence suggesting that Olr1 plays a role in the pathogenesis of atherosclerosis comes from the transgenic experiments. Recently, Inoue et al overexpressed the bovine Olr1 cDNA under endothelial specific promoter in mice which resulted in 10 fold increase in the size atheroma-like lesions in intramyocardial vessels of high fat diet fed transgenic animals (INOUE et al. 2005) . They, however, saw no statistical difference in lesions in the aorta of these animals which they attribute to lack of Olr1 overexpression in the aortic endothelial cells compared to myocardial vessel endothelial cells.
In addition to Ath37 and Ath38 which have strong effects on lesion formation, we were able to find evidence for the presence of at least two other genes with smaller effects at the telomeric end of the chromosome 6. These genes, however, seem to be linked in repulsion, meaning that the CAST allele of one of these genes is atheroprotective and the CAST allele of the other gene is atherogenic. There are no apparent candidate genes that we could identify in this 13.1 Mb region.
In summary, our data emphasize the complications that can arise in the genetic dissection of polygenic diseases such as atherosclerosis. Clearly, the chromosome 6 locus has a dramatic impact on atherosclerosis because it contains multiple genes contributing to the trait. Not only does the presence of closely linked genes affecting the same trait complicates the genetic analysis of the locus but also the interpretation of the results obtained from experiments with knock-out mice. 
